Neutralizing antibodies to HIV-1 and their use

US9738703B2 · kind B2 · utility

Assignees

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US
• University of Washington · US

Inventors

• John Mascola · Rockville, US
• Richard Wyatt · Village of La Jolla, US
• Xueling Wu · Potomac, US
• Yuxing Li · Boyds, US
• Carl-Magnus Hogerkorp · Vellinge, SE
• Mario Roederer · Bethesda, US
• Zhi-yong Yang · Potomac, US
• Gary J. Nabel · Cambridge, US
• Peter Kwong · Washington, US
• Tongqing Zhou · Boyds, US
• Mark Connors · Bethesda, US
• William R. Schief · Encinitas, US

Key dates

• Filing date: Sep 24, 2015
• Grant date: Aug 22, 2017
• Expiry date: Sep 24, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2740/16111
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Monoclonal neutralizing antibodies are disclosed that specifically bind to the CD4 binding site of HIV-1 gp120. Monoclonal neutralizing antibodies also are disclosed that specifically bind to HIV-1 gp41. The identification of these antibodies, and the use of these antibodies are also disclosed. Methods are also provided for enhancing the binding and neutralizing activity of any antibody using epitope scaffold probes.